IPSEN (OTCMKTS:IPSEY - Get Free Report) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $29.30 and traded as high as $30.01. IPSEN shares last traded at $30.01, with a volume of 312 shares traded.
Analyst Ratings Changes
Separately, Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of IPSEN in a research report on Wednesday, April 2nd.
Get Our Latest Stock Analysis on IPSEY
IPSEN Stock Performance
The stock has a 50 day moving average of $29.36 and a 200-day moving average of $29.31.
IPSEN Increases Dividend
The company also recently declared a dividend, which was paid on Wednesday, June 25th. Shareholders of record on Tuesday, June 10th were issued a dividend of $0.2896 per share. The ex-dividend date of this dividend was Monday, June 9th. This represents a yield of 0.97%. This is an increase from IPSEN's previous dividend of $0.23.
IPSEN Company Profile
(
Get Free Report)
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Featured Stories
Before you consider IPSEN, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IPSEN wasn't on the list.
While IPSEN currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
